2-(2-喹啉)丙二醛 | 40070-84-6

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-(2-喹啉)丙二醛
• 英文名称: 2-(quinolin-2-yl)malondialdehyde
• 英文别名: 2-(2-quinolinyl)malondialdehyde；2-(2-quinolyl)propandialdehyde；2-(quinolin-2-yl)malonaldehyde；2-quinolin-2-ylpropanedial
• CAS: 40070-84-6
• 化学式: C₁₂H₉NO₂
• mdl: MFCD01569245
• 分子量: 199.209
• InChiKey: BGCDOBZPKOBWHE-UHFFFAOYSA-N

物化性质

• 熔点：
  198-202 °C
• 沸点：
  336.72°C (rough estimate)
• 密度：
  1.1919 (rough estimate)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  47
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi,C
• 安全说明：
  S25,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2933499090
• 储存条件：
  存于阴凉干燥处

反应信息

• 作为反应物：
  描述：

  2-(2-喹啉)丙二醛 、 盐酸纳曲酮 在 乙酸铵 、 溶剂黄146 作用下， 反应 20.0h， 以22%的产率得到17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5α-epoxy-5'-(2-quinolinyl)pyrido[2',3':6,7]morphinan
  参考文献：
  名称：

  Novel ligands for the opioid receptors: synthesis and structure–activity relationships among 5′-aryl and 5′-heteroaryl 17-cyclopropylmethyl-4,5α-epoxypyrido[2′,3′:6,7]morphinans

  摘要：

  A series of pyridomorphinans possessing an aryl (10a-s) or heteroaryl (11a-h) substituent at the 5'-position of the pyridine ring of 17-cyclopropylmethyl-4,5alpha-epoxypyrido[2,3:6,7]morphinan was synthesized and evaluated for binding and functional activity at the opioid delta, mu, and kappa receptors. All of these pyridomorphinans bound with higher affinity at the delta site than at mu or kappa sites. The binding data on isomeric compounds revealed that there exists greater bulk tolerance for substituents placed at the o-position of the phenyl ring than at m- or p-positions. Among the ligands examined, the 2-chlorophenyl (101), 2-nitrophenyl (10n), 2-pyridyl (11a), and 4-quinolinyl (11g) compounds bound to the delta receptor with subnanomolar affinity. Compound 10c with the p-tolyl substituent displayed the highest mu/delta selectivity (ratio = 42) whereas compound 101 with the 2-chlorophenyl substituent displayed the highest kappa/delta selectivity (ratio 23). At 10 muM concentration, the in vitro functional activity determined using [S-35]GTP-gamma-S binding assays showed that all of the compounds were antagonists devoid of any significant agonist activity at the delta, mu, and kappa receptors. Antagonist potency determinations of three selected ligands revealed that the p-tolyl compound 10c is a potent 6 selective antagonist. In the [S-35]GTP-7-S assays this compound had a functional antagonist K-i value of 0.2, 4.52, and 7.62 nM at the delta, mu, and kappa receptors, respectively. In the smooth muscle assays 10c displayed delta antagonist potency with a K-e value of 0.88 nM. As an antagonist, it was 70-fold more potent at the 6 receptors in the MVD than at the mu receptors in the GPI. The in vitro delta antagonist profile of this pyridomorphinan 10c resembles that of the widely used delta selective antagonist ligand naltrindole. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00432-2
• 作为产物：
  描述：

  2-喹啉-2-基-丙烷-1,3-二醇 在 三氧化硫吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 2.0h， 以40%的产率得到2-(2-喹啉)丙二醛
  参考文献：
  名称：

  噁唑烷酮类化合物及其用途

  摘要：

  本发明提供了式VI所示的噁唑烷酮类化合物或其药学上可接受的盐、水合物或晶型。本发明还提供了化合物的制备方法。当前化药领域中，多数改变结构的化合物的活性会变好，但是毒性也会明显增强，无法作为药物使用。本发明所提供的化合物与现有的化合物相比，不仅能够有很好的抗耐药性和抗菌活性，令人意想不到的是，本发明的化合物安全性也更好，更有利于患者的用药安全和治疗。

  公开号：

  CN105399737B

文献信息

• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• Discovery of a Teraryl Oxazolidinone Compound (<i>S</i>)-<i>N</i>-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1<i>H</i>-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies
  作者：Tao Yang、Gong Chen、Zitai Sang、Yuanyuan Liu、Xiaoyan Yang、Ying Chang、Haiyue Long、Wei Ang、Jianying Tang、Zhenling Wang、Guobo Li、Shengyong Yang、Jingren Zhang、Yuquan Wei、Youfu Luo

  DOI：10.1021/acs.jmedchem.5b00152

  日期：2015.8.27

  A series of novel teraryl oxazolidinone compounds was designed, synthesized, and evaluated for their antimicrobial activity and toxicities. The compounds with aromatic N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compounds with different patterns of substitution. Among all potent compounds, 10f exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test. Furthermore, its phosphate was found to be highly soluble in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test. In MRSA systemic infection mice models, 10f phosphate exerted significantly improved survival protection compared with linezolid. The compound also demonstrated high oral bioavailability (F = 99.1%). Moreover, from the results of in vivo toxicology experiments, 10f phosphate would be predicted to have less bone marrow suppression.
• N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists
  作者：Elfatih Elzein、Rao Kalla、Xiaofen Li、Thao Perry、Tim Marquart、Mark Micklatcher、Yuan Li、Yuzhi Wu、Dewan Zeng、Jeff Zablocki

  DOI：10.1016/j.bmcl.2006.09.065

  日期：2007.1

  A series of new selective, high affinity A(1)-AdoR agonists is reported. Compound 23 that incorporated a carboxylic acid functionality in the 4-position of the pyrazole ring displayed K-iL value of 1 nM for the A(1)-AdoR and > 5000-fold selectivity over the A(3) and A(2A)-AdoRs. In addition, compound 19 that incorporated a carboxamide functionality in the 4-position of the pyrazole ring displayed subnanomolar affinity for the A(1)-AdoR (K-iL = 0.6 nM) and > 600-fold selectivity over the A(3) and A(2A)-AdoRs. (c) 2006 Elsevier Ltd. All rights reserved.
• 2-Pyrazolyl-N⁶-Substituted Adenosine Derivatives as High Affinity and Selective Adenosine A₃ Receptor Agonists
  作者：Elfatih Elzein、Venkata Palle、Yuzhi Wu、Tenning Maa、Dewan Zeng、Jeff Zablocki

  DOI：10.1021/jm049682h

  日期：2004.9.1

  We describe the synthesis of new high affinity and selective A(3)-adenosine receptor (A(3)-AdoR) agonists. Introduction of a methyl group at the N-6-position of the A(2A)-AdoR selective 2-pyrazolyladenosine analogues (Figure 2) brought about a substantial increase in the A(3)-AdoR binding affinity and selectivity. While the N-6-desmethyl analogues 3a and 4 were inactive at the A(3)AdoR (K-i > 10,muM), the corresponding N-6-methyl analogues 5 and 22 showed good binding affinity at the A(3)-AdoR (K-i = 73 and 97 nM, respectively). Replacement of the carboxamide group in 5 with different heteroaryl groups resulted in analogues with high affinities and selectivity for the A(3)-AdoR. (2R,3S,4R)-tetrahydro-2-(hydroxymethyl)-5-(6-(methylamino)-2-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)-9H-purin-9-yl)furan-3,4-diol (15, Ki = 2 nM) displayed high selectivity for the A(3)-AdoR versus A(1)- and A(2A)-AdoRs (selectivity ratios of 1900 and >2000, respectively).
• BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES
  申请人：Nuevolution A/S

  公开号：EP2558577A1

  公开（公告）日：2013-02-20